Roche has staked a claim to use its oral selective oestrogen receptor degrader (SERD) giredestrant as a second-line therapy for breast cancer, regardless of a patient's ESR1 mutation status. Top-line ...
Still pretending modesty and discretion work online? Look away. At 19, she’s clearly allergic to both, cheerfully flashing nine rather impossible inches while somehow looking sweeter than a cupcake ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback